Volume : 12, Issue : 11, November – 2025
Title:
EXCIPIENTS IN TABLET TECHNOLOGY: ROLES, CLASSIFICATION, AND FUNCTIONAL PROPERTIES
Authors :
Ajmera siroj Mulani*, Arati Bajarang Metkari, Ankita Bapu Lengare, Priya Bhaskar Gaikwad, Prerana Prakash Lokare, Sourabh Tukaram Waghmode
Abstract :
Excipients play a fundamental role in the design, development, and performance of tablet dosage forms. Once considered inert ingredients, they are now recognized as critical formulation components that influence the manufacturability, stability, bioavailability, and overall therapeutic efficacy of tablets. This comprehensive review highlights the significance of excipients in tablet technology, their classification based on function and chemical nature, and their physicochemical and functional properties. The evolution of excipients from simple fillers to multifunctional and engineered materials is discussed, emphasizing their impact on direct compression, disintegration, and controlled-release mechanisms. Special attention is given to novel and emerging excipient technologies, including co-processed excipients, natural and biopolymer-based materials, smart responsive excipients, and nanotechnology-compatible carriers. The evaluation parameters that determine flowability, compressibility, moisture sensitivity, and compatibility are elaborated to underline their influence on product quality. The review further explores recent advances and regulatory perspectives governing excipient selection and safety assessment. Overall, the article underscores the critical importance of rational excipient choice in achieving optimized, stable, and patient-compliant tablet formulations in modern pharmaceutical practice.
Keywords: Excipients; Tablet technology; Functional properties; Co-processed excipients; Natural polymers; Smart excipients; Flowability; Compressibility; Stability; Controlled-release systems.
Cite This Article:
Please cite this article in press Ajmera siroj Mulani et al., Excipients In Tablet Technology: Roles, Classification, And Functional Properties, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Liew K B, Hii S H, Uddin A B M H, Sarker Z I, Chew Y L. Co-processed excipients: a revisit of its development in the past two decades. J Pharm Neg Results. 2022;13(Special Issue 07):96-103.
2. Paka B, Sunitha Reddy M. A review on co-processed excipients used in direct compression of tablet dosage form. GSC Biol Pharm Sci. 2023;23(01):212-219.
3. Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast-disintegrating tablets: a review. Polim Med. 2023;53(1):59-68. doi:10.17219/pim/158009.
4. Mohite M, Sarnaik S, Lingayat A. Co-Processed Excipients – A Review. J Sci Tech. 2024;5(5):85-89. doi:10.46243/jst.2020.v5.i5.pp85-89.
5. Blessing Boma M, Fatima T Sambo, Zwanden Yahaya, Danjuma M. A novel co-processed excipient with enhanced direct compression functionality for improved diluent performance in ibuprofen tablets. ASRIC J Health Sci. 2023;3(1).
6. “2.2.1.P.4 Control of excipients” – Regulatory guideline excerpt, [Saudi FDA/ICH CTD section]. 2024. I
7. “Excipient Quality: Beyond the Pharmacopeia Monograph.” Tablets & Capsules MagazineAvailable online.
8. “Monographs – Indian Pharmacopoeia Commission.” Indian Pharmacopoeia Commission webpage; updated June 2024.
9. Fernandes A, [et al]. Performance evaluation of a novel biosourced co-processed excipient in direct compression and drug release. Polymers (MDPI). 2021;13(6):988. doi:10.3390/polym13060988.
10. Moradikouchi A, Sparén A, Svensson O, et al. Terahertz frequency-domain sensing combined with quantitative multivariate analysis for pharmaceutical tablet inspection. arXiv. 2022;abs/2212.09311.
11. [Insert your textbook or pharmaceutics standard reference here] — for example: Rowe R, Sheskey P, Quinn M, editors. Handbook of Pharmaceutical Excipients. 9th ed. London: Pharmaceutical Press; 2022.
12. Tiwari N, Rai V, Singh S. A Review on Herbal Excipients in Pharmaceutical Formulations. IASR J Med Pharm Sci. 2024;4(4):18-23.
13. Khairnar RG, Darade AR, Tasgaonkar RR. A review on tablet binders as a pharmaceutical excipient. World J Biol Pharm Health Sci. 2024;17(03):295-302.
14. Saianusha P, Sunitha Reddy M. A review on formulation and evaluation of tablets using natural excipients. IJARESM. 2022;10(2).
15. Sankeshwari S, H. V. G, A. S. K. M, Elyias A, Thirumaleshwar S, Pyda V H. A review on the solid oral dosage form for pediatrics, regulatory aspects, challenges involved during the formulation, and toxicity of the excipients used in pediatric formulation. Int J Appl Pharm. 2023;15(3):12-27.
16. Paka B, Sunitha Reddy M. A review on co-processed excipients used in direct compression of tablet dosage form. GSC Biol Pharm Sci. 2023;23(01):212-219. Study on the physical properties and application of a novel pharmaceutical excipient made from starch and cellulose co-processing. Pharmaceutics. 2024;18(9):1389.
17. Evaluation of the potential of novel co-processed excipients to enable direct compression and modified release of ibuprofen. Pharmaceutics. 2024;16(11):1473.
18. “A comprehensive review on pharmaceutical excipients.” PMC article. 2023/24.
19. “Co-processed excipients for direct compression of tablets.” Pharma Excipients review. 2018/19.
20. Sharma MC, Leel M. A Review Oral Dispersible Tablets. Int J Drug Dev Res. 2022;14(1).
21. Moradikouchi A, Sparén A, Svensson O, et al. Terahertz frequency-domain sensing combined with quantitative multivariate analysis for pharmaceutical tablet inspection. arXiv. 2022;abs/2212.09311.
22. Sun Text Reviews. Improvement of compaction behaviours of powder bed. SunText Rev. 2022.
23. “Cyclodextrins as excipients in tablet formulations.” Int J Pharm. 2018;553(1-2):271-281.
24. Bowles B, Dziemidowicz K, Lopez FL, Orlu M, Tuleu C, Ernest TB. Co-Processed Excipients for Dispersible Tablets – Part 1: Manufacturability. AAPS PharmSciTech. 2018;19(5):2127-2139.
25. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 9th ed. London: Pharmaceutical Press; 2022.
26. United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary (USP–NF). USP 46–NF 41. Rockville (MD): United States Pharmacopeial Convention; 2023.
27. European Pharmacopoeia Commission. European Pharmacopoeia 10.0. Strasbourg: Council of Europe; 2020.
28. Indian Pharmacopoeia Commission. Indian Pharmacopoeia (IP) 2018 – Addenda/monographs updates. Ghaziabad: IPC; latest updates 2023–2024.
29. IPEC-Federation. IPEC Safety Guide for Pharmaceutical Excipients. IPEC-Federation; 2021. Available from: https://ipec-federation.org/wp-content/uploads/2022/02/2021-IPEC-Safety-Guide-F.pdf.
30. IPEC-Federation. IPEC Validation Guide for Pharmaceutical Excipients. 2021. Available from: https://ipec-federation.org/guidelines.
31. Zhao H, Zhao L, Lin X, Shen L. An update on microcrystalline cellulose in direct compression: functionality, critical material attributes, and co-processed excipients. Carbohydrate Polymers. 2022;278:118968. doi:10.1016/j.carbpol.2021.118968.
32. Arshad MS, Rades T, Hook S. A review of emerging technologies enabling improved tablet manufacture and excipient performance. Int J Pharm. 2021;592:120072. doi:10.1016/j.ijpharm.2020.120072.
33. Janssen PHM, et al. Critical review on the role of excipient properties in pharmaceutical powder-to-tablet continuous manufacturing. Int J Pharm. 2024; [ePub]. doi:10.1080/17425247.2024.2384698.
34. Burande AS, Dhakare SP. A review on the role of co-processed excipients in tablet formulations. Hybrid Advances. 2024;7(21):100299. doi:10.1016/j.hybadv.2024.100299.
35. Pawar SB, et al. Review on novel pharmaceutical co-processed excipients. Pharma Excipients (rev. PDF). 2019. Available from: https://www.pharmaexcipients.com/wp-content/uploads/2019/11/Review-on-novel-pharmaceutical-co-processed-excipients.pdf.
36. Bowles B, Dziemidowicz K, Lopez FL, Orlu M, Tuleu C, Ernest TB. Co-processed excipients for dispersible tablets — part 1: manufacturability. AAPS PharmSciTech. 2018;19(5):2127–2139. doi:10.1208/s12249-018-1078-7.
37. Woyna-Orlewicz K, Brniak W, Tatara W, et al. Investigating the impact of co-processed excipients on formulation of orally disintegrating tablets. Pharm Res. 2023;40:2947–2962. doi:10.1007/s11095-023-03605-x.
38. Suksaeree J, et al. Microcrystalline cellulose promotes superior tablet performance: comparison of commonly used diluents. AAPS PharmSciTech. 2023;24:XX–XX. doi:10.1080/25765299.2022.2153527.
39. Fernandes A, et al. Performance evaluation of a novel biosourced co-processed excipient in direct compression and drug release. Polymers (MDPI). 2021;13(6):988. doi:10.3390/polym13060988.
40. Terzyk A, et al. Cyclodextrins as excipients in tablet formulations: solubilization and stability aspects. Int J Pharm. 2018;553(1–2):271–281. doi:10.1016/j.ijpharm.2018.10.025.
41. Gokhale R, et al. Advances of co-processed excipients: a review. Farmacia. 2020;68(5):987–999.
42. Thete PV, Channawar MA, Chandewar AV. Review on: Co-Processing of Excipients. Der Pharma Chemica. 2024;16(6):504–508.
43. Liew KB, Hii SH, Uddin ABM, Sarker ZI, Chew YL. Co-processed excipients: a revisit of its development in the past two decades. J Pharm Neg Results. 2022;13(Special Issue 07):96–103. doi:10.18231/j.pnr.2022.1686.
44. Paka B, Sunitha Reddy M. A review on co-processed excipients used in direct compression of tablet dosage form. GSC Biol Pharm Sci. 2023;23(01):212–219. doi:10.30574/gscbps.2023.23.1.0100.
45. Swami A, Chavan P, Chakankar S, Tagalpallewar A. A review on multifunctional excipients with regulatory considerations. J Pharm Res Int. 2021;33(45B):189–201. doi:10.9734/jpri/2021/v33i45B32796.
46. Sahrim PE, Mohamad RT, Guelfi M, et al. Multi-functional co-processed excipients for direct compression: design and applications. Int J Pharm. 2020;586:119564. doi:10.1016/j.ijpharm.2020.119564.
47. Moradikouchi A, Sparén A, Svensson O, et al. Terahertz frequency-domain sensing combined with quantitative multivariate analysis for pharmaceutical tablet inspection. Sensors. 2022;22:XXXX. doi:10.3390/s22165911.
48. Zhang J, et al. Effect of lubricant (magnesium stearate) on tablet tensile strength and dissolution: mechanistic studies. Eur J Pharm Biopharm. 2019;136:158–170. doi:10.1016/j.ejpb.2018.12.003.
49. Gupta A, et al. Impact of particle size and shape on powder flow and tablet properties: a comprehensive study. Powder Technol. 2020;364:542–553. doi:10.1016/j.powtec.2019.11.045.
50. Sreenivasan N, et al. Natural polymer excipients (chitosan, alginate, guar gum) in tablet technology — recent trends. Carbohydr Polym. 2021;259:117754. doi:10.1016/j.carbpol.2020.117754.
51. Benameur H, et al. Smart excipients: stimuli-responsive polymers for oral controlled release. J Control Release. 2022;345:514–529. doi:10.1016/j.jconrel.2022.02.031.
52. European Medicines Agency (EMA). Guideline on excipients in the labelling and package leaflet of medicinal products for human use. EMA/CHMP; 2019. Available from: https://www.ema.europa.eu.
53. International Council for Harmonisation (ICH). M7(R2) Assessment and control of DNA reactive (mutagenic) impurities. ICH; 2020. Available from: https://www.ich.org.
54. USP Expert Panel. Excipient performance and compendial monographs — perspective. Pharmacopeial Forum. 2020;46(6):847–859.
55. Lechuga-Bueno V, et al. Evaluation of superdisintegrants (crospovidone, croscarmellose sodium) in fast disintegrating tablets. AAPS PharmSciTech. 2019;20:286. doi:10.1208/s12249-019-1379-7.
56. Tiwari N, Rai V, Singh S. Herbal excipients in pharmaceutical formulations: a review. Asian J Pharm Clin Res. 2022;15(12):10–18.
57. Khairnar RG, Darade AR, Tasgaonkar RR. A review on tablet binders as pharmaceutical excipient. World J Biol Pharm Health Sci. 2024;17(3):295–302.
58. Morlock M, et al. Analytical methods for excipient characterization: DSC, FTIR, TGA, XRPD applications. J Pharm Biomed Anal. 2021;190:113533. doi:10.1016/j.jpba.2020.113533.
59. Bhowmik D, et al. Effect of excipient–API compatibility on stability and shelf-life: case studies. Int J Pharm. 2020;586:119595. doi:10.1016/j.ijpharm.2020.119595.
60. European Directorate for the Quality of Medicines (EDQM). Pharmacopoeia monographs and general chapters (Ph. Eur.). 10th ed.; latest updates 2022.
61. Sinha VR, Kaur MP. Moisture sorption behaviour of common pharmaceutical excipients and its impact on tablet properties. AAPS PharmSciTech. 2019;20:195. doi:10.1208/s12249-019-1363-1.
62. Koo OM, et al. Nanotechnology-compatible excipients for oral solid dosage forms: surfactants and stabilizers. J Pharm Sci. 2020;109:2345–2360. doi:10.1016/j.xphs.2020.04.012.
63. Williams RO 3rd, et al. Excipients in drug delivery: the key to formulation success. Adv Drug Deliv Rev. 2018;136–137:1–2. doi:10.1016/j.addr.2018.01.002.
64. Thombre R, et al. Direct compression excipients: recent developments and industrial perspectives. Drug Dev Ind Pharm. 2021;47(7):1103–1116. doi:10.1080/03639045.2021.1911618.
65. FDA. Guidance for Industry — Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. U.S. Food & Drug Administration; 2019. Available from: https://www.fda.gov.
66. IPEC-PQG. Joint IPEC-PQG GMP Guide for Pharmaceutical Excipients. 2016 (updated). Available from: https://health.ec.europa.eu/system/files/2016-11/111_b_international_pharmaceutical_excipients_council_en_0.pdf.
67. Vannucchi M, et al. Co-processed excipients for direct compression: evaluation of dilution potential and tablet robustness. J Pharm Innov. 2022;17:543–556. doi:10.1007/s12247-021-09550-7.
68. Patel RP, et al. Role of excipients in taste masking: techniques and excipient choices. Drug Dev Ind Pharm. 2019;45(9):1400–1410. doi:10.1080/03639045.2019.1654963.
69. Mönkkönen J, et al. Regulatory perspectives on novel excipients: industry and EMA/ FDA initiatives. Regul Toxicol Pharmacol. 2020;115:104686. doi:10.1016/j.yrtph.2020.104686.